TAVR Highlights: Cardiologists & heart surgeons sound the alarm | A key approval for Medtronic | New data on stroke risk

Are too many low-risk patients with severe AS undergoing TAVR instead of SAVR? According to one group of clinicians, "a significant public health concern may be looming."

Medtronic developed the self-expanding Evolut FX+ TAVR system with improved coronary access in mind. The FDA-approved device has now officially launched in India. 

TAVR reintervention rates remain low. However, they are slowly rising as the procedure is used more to treat patients with severe aortic stenosis. Researchers think this trend may continue going forward.

Screening TAVR patients for CAS may provide significant value, according to a new meta-analysis of 15 different studies.

Should patients with excessive cusp calcification be treated with self-expanding or balloon-expandable TAVR devices? Each valve type appears to be associated with its own benefits and risks.

More research is still needed, as this study only included data from a small number of patients, but TAVR was not linked to any severe adverse events or allergic reactions.

New research suggests there may be a cardiovascular benefit to considering dual antiplatelet therapy for valve-in-valve TAVR patients.

More and more TAVR patients are going to require SAVR later in life. A research team out of Cleveland Clinic hoped to learn more about how this one-two combination may impact long-term outcomes.